Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LN-144||Lifileucel||LN-144 (Lifileucel) is a preparation of tumor infiltrating lymphocytes isolated and expanded from patient tumor tissue, which may demonstrate enhanced anti-tumor immune activity when re-introduced into patients (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 3045-3045).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||LN-144||Phase II||Actionable||In a Phase II trial, LN-144 treatment resulted in an objective response rate of 33% (3/9, 1 complete response, 2 partial response) in patients with advanced metastatic melanoma (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 3045-3045; NCT02360579).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02360579||Phase II||LN-144||Study of LN-144, Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144)||Active, not recruiting||USA||7|